SUTRO BIOPHARMA, INC. Revenue
SUTRO BIOPHARMA, INC. (STRO) reported Revenue of $9.84 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-12
- SUTRO BIOPHARMA, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $9.84M, a 84.57% decline year-over-year.
- SUTRO BIOPHARMA, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $14.52M, a 16.53% decline year-over-year.
- SUTRO BIOPHARMA, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $11.65M, a 21.35% decline year-over-year.
- SUTRO BIOPHARMA, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $9.69M, a 13.77% increase year-over-year.
- SUTRO BIOPHARMA, INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $102.48M, a 65.18% increase from fiscal 2024.
- SUTRO BIOPHARMA, INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $62.04M, a 59.64% decline from fiscal 2023.
- SUTRO BIOPHARMA, INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $153.73M, a 126.84% increase from fiscal 2022.
- SUTRO BIOPHARMA, INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $67.77M, a 9.52% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.84M 10-Q · filed 2026-08-12 | $24.36M 10-Q · filed 2026-08-12 | $36.01M derived: sum of 3 quarters · filed 2026-08-12 | $45.70M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $14.52M 10-Q · filed 2026-05-14 | $26.17M derived: sum of 2 quarters · filed 2026-05-14 | $35.86M derived: sum of 3 quarters · filed 2026-05-14 | $99.61M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $11.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $21.34M derived: sum of 2 quarters · filed 2026-03-23 | $85.08M derived: sum of 3 quarters · filed 2026-08-12 | $102.48M 10-K · filed 2026-03-23 |
| 2025-09-30 | $9.69M 10-Q · filed 2025-11-06 | $73.44M derived: sum of 2 quarters · filed 2026-08-12 | $90.84M 10-Q · filed 2025-11-06 | $105.65M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $63.74M 10-Q · filed 2026-08-12 | $81.14M 10-Q · filed 2026-08-12 | $95.95M derived: sum of 3 quarters · filed 2026-08-12 | $104.47M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $17.40M 10-Q · filed 2026-05-14 | $32.21M derived: sum of 2 quarters · filed 2026-05-14 | $40.73M derived: sum of 3 quarters · filed 2026-05-14 | $66.43M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $14.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $23.33M derived: sum of 2 quarters · filed 2026-03-23 | $49.03M derived: sum of 3 quarters · filed 2026-03-23 | $62.04M 10-K · filed 2026-03-23 |
| 2024-09-30 | $8.52M 10-Q · filed 2025-11-06 | $34.23M derived: sum of 2 quarters · filed 2025-11-06 | $47.23M 10-Q · filed 2025-11-06 | $160.96M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $25.71M 10-Q · filed 2025-08-07 | $38.71M 10-Q · filed 2025-08-07 | $152.44M derived: sum of 3 quarters · filed 2025-08-07 | $169.36M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $13.01M 10-Q · filed 2025-05-08 | $126.73M derived: sum of 2 quarters · filed 2025-05-08 | $143.65M derived: sum of 3 quarters · filed 2025-05-08 | $154.06M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $113.72M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $130.65M derived: sum of 2 quarters · filed 2025-03-13 | $141.06M derived: sum of 3 quarters · filed 2025-03-13 | $153.73M 10-K · filed 2025-03-13 |
| 2023-09-30 | $16.92M 10-Q · filed 2024-11-13 | $27.34M derived: sum of 2 quarters · filed 2024-11-13 | $40.01M 10-Q · filed 2024-11-13 | $48.64M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | $10.41M 10-Q · filed 2024-08-13 | $23.09M 10-Q · filed 2024-08-13 | $31.72M derived: sum of 3 quarters · filed 2025-03-13 | $56.87M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | $12.67M 10-Q · filed 2024-05-13 | $21.31M derived: sum of 2 quarters · filed 2025-03-13 | $46.45M derived: sum of 3 quarters · filed 2025-03-13 | $74.55M derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | $8.63M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $33.78M derived: sum of 2 quarters · filed 2025-03-13 | $61.88M derived: sum of 3 quarters · filed 2025-03-13 | $67.77M 10-K · filed 2025-03-13 |
| 2022-09-30 | $25.15M 10-Q · filed 2023-11-13 | $53.24M derived: sum of 2 quarters · filed 2023-11-13 | $59.14M 10-Q · filed 2023-11-13 | $69.79M derived: sum of 4 quarters · filed 2024-03-25 |
| 2022-06-30 | $28.10M 10-Q · filed 2023-08-10 | $33.99M 10-Q · filed 2023-08-10 | $44.65M derived: sum of 3 quarters · filed 2024-03-25 | $53.16M derived: sum of 4 quarters · filed 2024-03-25 |
| 2022-03-31 | $5.90M 10-Q · filed 2023-05-15 | $16.55M derived: sum of 2 quarters · filed 2024-03-25 | $25.07M derived: sum of 3 quarters · filed 2024-03-25 | $53.12M derived: sum of 4 quarters · filed 2024-03-25 |
| 2021-12-31 | $10.65M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $19.17M derived: sum of 2 quarters · filed 2024-03-25 | $47.22M derived: sum of 3 quarters · filed 2024-03-25 | $61.88M 10-K · filed 2024-03-25 |
| 2021-09-30 | $8.52M 10-Q · filed 2022-11-08 | $36.57M derived: sum of 2 quarters · filed 2022-11-08 | $51.23M 10-Q · filed 2022-11-08 | $59.50M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $28.05M 10-Q · filed 2022-08-08 | $42.71M 10-Q · filed 2022-08-08 | $50.99M derived: sum of 3 quarters · filed 2022-08-08 | $68.81M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $14.66M 10-Q · filed 2022-05-09 | $22.94M derived: sum of 2 quarters · filed 2022-05-09 | $40.76M derived: sum of 3 quarters · filed 2022-05-09 | $50.23M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $8.28M 10-K · filed 2021-03-18 | $26.10M derived: sum of 2 quarters · filed 2021-11-10 | $35.57M derived: sum of 3 quarters · filed 2021-11-10 | $42.72M 10-K · filed 2023-03-30 |
| 2020-09-30 | $17.82M 10-Q · filed 2021-11-10 | $27.29M derived: sum of 2 quarters · filed 2021-11-10 | $34.44M 10-Q · filed 2021-11-10 | $45.75M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $9.47M 10-Q · filed 2021-08-09 | $16.62M 10-Q · filed 2021-08-09 | $27.93M derived: sum of 3 quarters · filed 2021-08-09 | $40.20M derived: sum of 4 quarters · filed 2021-08-09 |
| 2020-03-31 | $7.15M 10-Q · filed 2021-05-07 | $18.46M derived: sum of 2 quarters · filed 2021-05-07 | $30.73M derived: sum of 3 quarters · filed 2021-05-07 | $41.26M derived: sum of 4 quarters · filed 2021-05-07 |
| 2019-12-31 | $11.30M 10-K · filed 2021-03-18 | $23.58M derived: sum of 2 quarters · filed 2021-03-18 | $34.11M derived: sum of 3 quarters · filed 2021-03-18 | $42.74M 10-K · filed 2022-02-28 |
| 2019-09-30 | $12.28M 10-K · filed 2021-03-18 | $22.80M derived: sum of 2 quarters · filed 2021-03-18 | $31.43M 10-Q · filed 2020-11-05 | $50.52M derived: sum of 4 quarters · filed 2021-03-18 |
| 2019-06-30 | $10.53M 10-K · filed 2021-03-18 | $19.15M 10-Q · filed 2020-08-06 | $38.24M derived: sum of 3 quarters · filed 2021-03-18 | $46.08M derived: sum of 4 quarters · filed 2021-03-18 |
| 2019-03-31 | $8.63M 10-K · filed 2021-03-18 | $27.71M derived: sum of 2 quarters · filed 2021-03-18 | $35.55M derived: sum of 3 quarters · filed 2021-03-18 | $41.26M derived: sum of 4 quarters · filed 2021-03-18 |
| 2018-12-31 | $19.09M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $26.92M derived: sum of 2 quarters · filed 2021-03-18 | $32.63M derived: sum of 3 quarters · filed 2021-03-18 | $38.42M 10-K · filed 2021-03-18 |
| 2018-09-30 | $7.84M 10-Q · filed 2019-11-08 | $13.54M derived: sum of 2 quarters · filed 2019-11-08 | $19.33M 10-Q · filed 2019-11-08 | |
| 2018-06-30 | $5.70M 10-Q · filed 2019-08-14 | $11.50M 10-Q · filed 2019-08-14 | ||
| 2018-03-31 | $5.79M 10-Q · filed 2019-05-15 | |||
| 2017-12-31 | $51.74M 10-K · filed 2020-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |